Pipeline dossier

NIH & clinical-trial pipeline signals for NOVO NORDISK A S (NVO)

Leading indicators across the NIH grant → clinical trial → SEC filing chain for NVO, mapped to public ticker NVO (CIK 0000353278). Sourced live from public data.

⚠ Research/informational signals from public data (NIH · ClinicalTrials.gov · SEC EDGAR). Not investment advice. Full scope →

Trial → FilingNVO55% conf

NOVO NORDISK A S (NVO) — PHASE1 primary completion in ~143 days

Upstream (observed)
Clinical trial status (PHASE1) — A Research Study Investigating How a New Medicine NNC0113-5840 Works in People With Overweight or Obesity

↓ Phase-transition base rate 52% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on Phase 2 readout / advance (12-24 mo, base rate 52%)

trial ↗filings ↗

Trial → FilingNVO35% conf

NOVO NORDISK A S (NVO) — PHASE3 protocol updated 1 days ago

Upstream (observed)
Clinical trial status (PHASE3) — AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight

↓ Phase-transition base rate 57% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on NDA/BLA filing (FDA submission) (12-24 mo, base rate 57%)

trial ↗filings ↗

Trial → FilingNVO35% conf

NOVO NORDISK A S (NVO) — PHASE3 protocol updated 1 days ago

Upstream (observed)
Clinical trial status (PHASE3) — AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea

↓ Phase-transition base rate 57% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on NDA/BLA filing (FDA submission) (12-24 mo, base rate 57%)

trial ↗filings ↗

Trial → FilingNVO35% conf

NOVO NORDISK A S (NVO) — PHASE3 protocol updated 2 days ago

Upstream (observed)
Clinical trial status (PHASE3) — Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide

↓ Phase-transition base rate 57% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on NDA/BLA filing (FDA submission) (12-24 mo, base rate 57%)

trial ↗filings ↗

Trial → FilingNVO35% conf

NOVO NORDISK A S (NVO) — PHASE3 protocol updated 1 days ago

Upstream (observed)
Clinical trial status (PHASE3) — A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes

↓ Phase-transition base rate 57% (Wong/Siah/Lo 2019)

Predicted downstream
SEC 8-K / press release on NDA/BLA filing (FDA submission) (12-24 mo, base rate 57%)

trial ↗filings ↗

JSON API for this entity →